tweenvest

BioAtla, Inc. (OTCPK: BCAB)

Health Care · Biotechnology · US

$1.35

-24.78% today · -97.8% 1Y

Public summary
A free snapshot of BioAtla, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

BioAtla, Inc. (OTCPK: BCAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.26M and employs 41 people.

Over the last twelve months the share price has lost 97.8%, trading between 1.07 and 71.50.

Tweenvest scores BioAtla, Inc. across four factors: quality 10/100, value 63/100. Its strongest factor is value.

BCAB price history

Nov 21, 2025 · 43.46Weekly closes 1.31 – 45.20Nov 18, 2026 · 1.35

Key figures

Market cap
$2.26M
Revenue (TTM)
$8.75M
P/E
-0.07
EPS
-16.88
Dividend yield
—
Beta (5Y)
0.50
52-week high
$71.50
52-week low
$1.07
Avg volume (3M)
—
Shares outstanding
1.67M
Employees
41
Next earnings
—

About BioAtla, Inc.

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

ISIN
US09077B2034
Founded
2007
Listed since
Dec 16, 2020
Exchange
Pink Sheets LLC
Currency
USD
CompanyMarket capPriceDay
ValiRx plcAIM: VAL$2.44M£0.00-9.68%
Quest PharmaTech Inc.TSXV: QPT$2.37MCA$0.020.00%
ExpreS2ion Biotech Holding AB (publ)OM: EXPRS2$2.34MSkr0.99+3.13%
BSF Enterprise PlcLSE: BSFA$2.28M£0.01-10.00%
Predilife S.A.ENXTPA: ALPRE$2.25M€0.52-10.65%
Vectus Biosystems LimitedASX: VBS$2.23MAU$0.05+6.00%
Cynata Therapeutics LimitedASX: CYP$2.15MAU$0.010.00%
Transgene Biotek LimitedBSE: 526139$2.12MRs2.64+3.53%

Browse every Biotechnology company →